CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)	Total	Common Stock Class A [Member]	Common Stock Class B Shares [Member]	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehesive Income (Loss)
Balance, shares at Dec. 31, 2020		117,000,000
Balance, amount at Dec. 31, 2020	$ 1,167,619	$ 117,000	$ 0	$ 1,991,617	$ (942,994)	$ 1,996
Capital contirubtions to Yubo Beijing	127,164	$ 0	$ 0	127,164	0	0
Reverse acquisition of Yubo International Biotech Limited by Platinum International Biotech Co. Ltd., shares		1,177,885	4,447
Reverse acquisition of Yubo International Biotech Limited by Platinum International Biotech Co. Ltd., amount	0	$ 1,178	$ 4	(1,182)	0	0
Net loss for the three months ended March 31	(438,675)	$ 0	$ 0	0	(438,675)	0
Foreign currency adjustment	70,413					70,413
Balance, shares at Mar. 31, 2021		118,177,885	4,447
Balance, amount at Mar. 31, 2021	926,521	$ 118,178	$ 4	2,117,599	(1,381,669)	72,409
Balance, shares at Dec. 31, 2021		118,177,885	4,447
Balance, amount at Dec. 31, 2021	(131,198)	$ 118,178	$ 4	2,117,599	(2,485,432)	118,453
Net loss for the three months ended March 31	(578,948)	0	0	0	(578,948)	0
Foreign currency adjustment	(49,977)	$ 0	$ 0	0	0	(49,977)
Balance, shares at Mar. 31, 2022		118,177,885	4,447
Balance, amount at Mar. 31, 2022	$ (760,123)	$ 118,178	$ 4	$ 2,117,599	$ (3,064,380)	$ 68,476